skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 7
Patent #:
10968192
Issue Dt:
04/06/2021
Application #:
16579106
Filing Dt:
09/23/2019
Publication #:
20200255394
Pub Dt:
08/13/2020
Inventors:
Mark Stephen BEDNARZ, Kuangchu DAI, Jeffrey Manning ECKERT, Ngiap-Kie LIM et al
Title:
CRYSTALLINE SOLID FORMS OF N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-((2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL)PHENYL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS
Assignment: 1
Reel/Frame:
054352/0490Recorded: 11/12/2020Pages: 2
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
KUANGCHU, DAI
Exec Dt:
09/23/2020
Assignee:
STA PHARMACEUTICAL HONG KONG LIMITED
288, FUTE ZHONG ROAD
WAIGAOQUIAO FREETRADE ZONE
SHANGHAI, CHINA 200131
Correspondent:
MAX BACHRACH
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160
Assignment: 2
Reel/Frame:
055174/0522Recorded: 01/29/2021Pages: 3
Conveyance:
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME AND ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 054352 FRAME: 0490. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT .
Assignor:
DAI, KUANGCHU
Exec Dt:
09/23/2020
Assignee:
STA PHARMACEUTICAL HONG KONG LIMITED
304 DOMINION CENTRE, 43 QUEEN'S ROAD EAST
WANCHAI, HONG KONG
Correspondent:
MAX BACHRACH
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160
Assignment: 3
Reel/Frame:
054352/0754Recorded: 11/12/2020Pages: 2
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
STA PHARMACEUTICAL HONG KONG LIMITED
Exec Dt:
09/27/2020
Assignee:
LEXICON PHARMACEUTICALS (NEW JERSEY), INC.
110 ALLEN ROAD
4TH FLOOR
BASKING RIDGE, NEW JERSEY 07920
Correspondent:
MAX BACHRACH
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160
Assignment: 4
Reel/Frame:
054352/0884Recorded: 11/12/2020Pages: 2
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
LEXICON PHARMACEUTICALS (NEW JERSEY), INC.
Exec Dt:
10/29/2020
Assignee:
LEXICON PHARMACEUTICALS, INC.
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TEXAS 77381
Correspondent:
MAX BACHRACH
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160
Assignment: 5
Reel/Frame:
055457/0565Recorded: 03/02/2021Pages: 10
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
ECKERT, JEFFREY MANNING
Exec Dt:
11/02/2020
LIM, NGIAP-KIE
Exec Dt:
11/04/2020
SIROIS, LAUREN
Exec Dt:
11/02/2020
WU, WENXUE
Exec Dt:
10/29/2020
ZHAO, MATTHEW MANGZHU
Exec Dt:
11/04/2020
Assignee:
LEXICON PHARMACEUTICALS, INC.
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TEXAS 77381
Correspondent:
MAX BACHRACH
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160
Assignment: 6
Reel/Frame:
055707/0295Recorded: 03/24/2021Pages: 9
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
BEDNARZ, MARK STEPHEN
Exec Dt:
03/03/2021
Assignee:
LEXICON PHARMACEUTICALS, INC.
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TEXAS 77381
Correspondent:
MAX BACHRACH
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160
Assignment: 7
Reel/Frame:
059432/0709Recorded: 03/17/2022Pages: 10
Conveyance:
SECURITY INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
LEXICON PHARMACEUTICALS, INC.
Exec Dt:
03/17/2022
Assignee:
OXFORD FINANCE LLC, AS COLLATERAL AGENT
115 SOUTH UNION STREET, SUITE 300
ATTN: LEGAL DEPARTMENT
ALEXANDRIA, VIRGINIA 22314
Correspondent:
BARNES & THORNBURG LLP
655 WEST BROADWAY
ATTN: HILLARY KOOY
SAN DIEGO, CA 92101

Search Results as of: 05/28/2024 04:59 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT